Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxinA: A prospective controlled study

Bibliographic Information
Authors: Hamoda T.A.-A.A.-M.; Mosli H.A.; Farsi H.; Alsayyad A.; Tayib A.; Sait M.; Abdelsalam A.
Journal: Canadian Journal of Urology
Publisher: Canadian Journal of Urology
Publication Date: 2018
Volume / Issue: Volume 25 / Issue 2
Pages: 9273–9280
ISSN: 11959479
Scopus: View on Scopus
PubMed: 29680006
Document Type: Article
Authors and Affiliations
Hamoda T.A.-A.A.-M., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, Department of Urology, Minia University, El Minia, Egypt; Mosli H.A., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Farsi H., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Alsayyad A., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Tayib A., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Sait M., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Abdelsalam A., Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, Department of Urology, Theodor Bilharz Research Institute, Cairo, Egypt
Abstract
Introduction: To evaluate the efficacy and safety of intraprostatic injections of onabotulinumtoxinA (onaBoNT-A) to treat refractory chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Materials and methods: Prospective two-group controlled study. Treatment group included adult men with refractory category-III nonbacterial CP/CPPS who underwent transurethral intraprostatic injections of onaBoNT-A (200 U). Control group included comparable patients who underwent cystoscopy only. Primary outcome was the proportion of 6-point responders (= 6 points reduction of total score of National Institutes of Health-Chronic Prostatitis Symptom Index [NIH-CPSI]), at 3 months. Secondary outcomes included proportions of quality of life (QoL) responders (≤ 2 points in QoL domain), and global response assessment (GRA) responders (patients reporting moderately improved, or markedly improved), at 3 months. Other outcomes comprised changes from baseline NIH-CPSI scores, visual analog scale (VAS) sub-score of pain domain, PSA, prostate volume, post-void residual urine, and maximum flow rate. Significance was set at p < 0.05. Results: Treatment group included 43 patients with mean age (SD) of 38.8 (7.3) years and mean duration of symptoms of 7.0 (2.9) years. At 3 months, the proportions of responders (NIH-CPSI 6-point, QoL, and GRA) were 72.1%, 69.8%, and 72.1%; which gradually declined to 37.2%, 25.7% and 27.9%, respectively, at 12 months. The baseline NIH-CPSI total score demonstrated -68.2% reduction at 3 months (-20.1 points; p < 0.0001); which gradually waned to -19% reduction (-5.6 points; p < 0.0001) at 12 months. Baseline VAS showed -79%, and -27.4% reductions at 3 and 12 months, respectively (p < 0.0001, each). None of control men has been 6-point, QoL nor GRA responder and none has demonstrated significant NIH-CPSI scores changes from baseline (p > 0.05, each). Compared to control, mean NIH-CPSI total scores of treated men at 1 and 3 months were significantly different (p < 0.001, each). Conclusion: OnaBoNT-A intraprostatic injections appeared to be effective and safe to ameliorate symptoms of refractory nonbacterial CP/CPPS; with pain most improved. The improvements gradually dwindled at 9-12 months. © The Canadian Journal of Urology™.
Keywords
Chronic prostatitis symptom index; Chronic prostatitis/chronic pelvic pain syndrome; OnabotulinumtoxinA; Adult; Botulinum Toxins, Type A; Chronic Disease; Chronic Pain; Cystoscopy; Humans; Injections, Intralesional; Male; Middle Aged; Pain Measurement; Pelvic Pain; Prospective Studies; Prostatitis; Quality of Life; Reference Values; Risk Assessment; Syndrome; Treatment Outcome; botulinum toxin A; complication; controlled clinical trial; controlled study; human; intralesional drug administration; microbiology; procedures; prospective study; reference value
Citation Information
Scopus Citations: 21
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
